386 related articles for article (PubMed ID: 24470531)
1. Malignant peripheral nerve sheath tumors.
Farid M; Demicco EG; Garcia R; Ahn L; Merola PR; Cioffi A; Maki RG
Oncologist; 2014 Feb; 19(2):193-201. PubMed ID: 24470531
[TBL] [Abstract][Full Text] [Related]
2. Systemic Options for Malignant Peripheral Nerve Sheath Tumors.
Hassan A; Pestana RC; Parkes A
Curr Treat Options Oncol; 2021 Feb; 22(4):33. PubMed ID: 33641042
[TBL] [Abstract][Full Text] [Related]
3. [Targeted therapy for malignant peripheral nerve sheath tumor: translational research and clinical application].
Liao ZC; Zhang C; Liu XY; Ren ZW; Xu J; Zhang CZ; Yang Y; Zhu Z; Yang JL
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):648-653. PubMed ID: 31550853
[TBL] [Abstract][Full Text] [Related]
4. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways.
Katz D; Lazar A; Lev D
Expert Rev Mol Med; 2009 Oct; 11():e30. PubMed ID: 19835664
[TBL] [Abstract][Full Text] [Related]
5. Malignant peripheral nerve sheath tumor: models, biology, and translation.
Somatilaka BN; Sadek A; McKay RM; Le LQ
Oncogene; 2022 Apr; 41(17):2405-2421. PubMed ID: 35393544
[TBL] [Abstract][Full Text] [Related]
6. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
7. Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.
Reuss DE; Habel A; Hagenlocher C; Mucha J; Ackermann U; Tessmer C; Meyer J; Capper D; Moldenhauer G; Mautner V; Frappart PO; Schittenhelm J; Hartmann C; Hagel C; Katenkamp K; Petersen I; Mechtersheimer G; von Deimling A
Acta Neuropathol; 2014 Apr; 127(4):565-72. PubMed ID: 24464231
[TBL] [Abstract][Full Text] [Related]
8. Malignant Peripheral Nerve Sheath Tumor Arising Within Lumbar Spinal Plexiform Neurofibroma.
Alves Júnior SF; Pessoa Corrêa JA; Marchiori E
World Neurosurg; 2019 Oct; 130():264-266. PubMed ID: 31323411
[TBL] [Abstract][Full Text] [Related]
9. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
10. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
11. Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside.
Martin E; Lamba N; Flucke UE; Verhoef C; Coert JH; Versleijen-Jonkers YMH; Desar IME
Crit Rev Oncol Hematol; 2019 Jun; 138():223-232. PubMed ID: 31092379
[TBL] [Abstract][Full Text] [Related]
12. Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations.
Grobmyer SR; Reith JD; Shahlaee A; Bush CH; Hochwald SN
J Surg Oncol; 2008 Mar; 97(4):340-9. PubMed ID: 18286466
[TBL] [Abstract][Full Text] [Related]
13. Management of childhood malignant peripheral nerve sheath tumor.
Ferrari A; Bisogno G; Carli M
Paediatr Drugs; 2007; 9(4):239-48. PubMed ID: 17705563
[TBL] [Abstract][Full Text] [Related]
14. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
[TBL] [Abstract][Full Text] [Related]
15. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
[TBL] [Abstract][Full Text] [Related]
16. Methylation-based classification of benign and malignant peripheral nerve sheath tumors.
Röhrich M; Koelsche C; Schrimpf D; Capper D; Sahm F; Kratz A; Reuss J; Hovestadt V; Jones DT; Bewerunge-Hudler M; Becker A; Weis J; Mawrin C; Mittelbronn M; Perry A; Mautner VF; Mechtersheimer G; Hartmann C; Okuducu AF; Arp M; Seiz-Rosenhagen M; Hänggi D; Heim S; Paulus W; Schittenhelm J; Ahmadi R; Herold-Mende C; Unterberg A; Pfister SM; von Deimling A; Reuss DE
Acta Neuropathol; 2016 Jun; 131(6):877-87. PubMed ID: 26857854
[TBL] [Abstract][Full Text] [Related]
17. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
18. Current treatment options for malignant peripheral nerve sheath tumors.
Bradford D; Kim A
Curr Treat Options Oncol; 2015 Mar; 16(3):328. PubMed ID: 25777573
[TBL] [Abstract][Full Text] [Related]
19. Intraosseous malignant peripheral nerve sheath tumor in a patient with neurofibromatosis.
Terry DG; Sauser DD; Gordon MD
Skeletal Radiol; 1998 Jun; 27(6):346-9. PubMed ID: 9677654
[TBL] [Abstract][Full Text] [Related]
20. Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review.
Ziadi A; Saliba I
Auris Nasus Larynx; 2010 Oct; 37(5):539-45. PubMed ID: 20399579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
